Study of CM310 in Children Subjects With Moderate-to-severe Atopic Dermatis

Summary

This is a multi-center, single arm, open-label study to evaluate safety in children patients with moderate-to severe atopic dermatis.

Timeline

Start

2023-12-22

Primary completion

2024-07-04

Completion

2024-07-04

Publications

• Zhao M, Xu Z, Wu L, Wei Z, Yang B, Lin Z, Ding Y, Hu G, Wang H, Qian Q, Ran Q, Li X, Xu Y, Xu Y, Huang Y, Jia Y, Chen B, Ma L. Safety and efficacy of stapokibart, an anti-interleukin-4 receptor alpha monoclonal antibody, in children aged 6-11 years with moderate-to-severe atopic dermatitis: an open-label single-arm phase Ib/IIa trial. Br J Dermatol. 2026 Mar 19;194(4):621-628. doi: 10.1093/bjd/ljaf455.

Drugs

Indications